How Will The PD-L1 Test Market Develop? | Diaceutics

How Will The PD-L1 Test Market Develop?

November 10th, 2016

PDL1 market blog image


The significant interest shown in the Diaceutics webinar How Can Analytics Help Avoid the PD-L1 Chaos: 10 Years of Insights is evidence of the widespread impact PD-L1 testing is already having on personalized medicine. Many of the issues surrounding PD-L1 that are discussed in the webinar have been seen in previous biomarker programs, but for the first time we have been able to track the clinical and competitive impact.

The webinar discussed the potential hyperconnectivity of the biomarker and looked to the next few years of test market development. Diaceutics were able to make predictions to 2020 about areas such as adoption, integration in NSCLC, financial dynamics and prescriber behaviour. This was made possible by employing real time observations gathered from analogues, laboratory data, diagnostic information and competitive intelligence.

In addition, an AntiPD-1 longitudinal prescriber panel of 30 Opdivo/Keytruda prescribers was set up to obtain first hand opinions on their interface with testing. This approach has enabled Diaceutics to predict trends based on a hectic first few years of PD-L1 testing market development and an increasingly dynamic landscape moving forward.

Despite the uncertainties hanging over the first generation of diagnostic tests, Diaceutics believes the landscape will develop to require ever more PD-L1 testing and that PD-L1 will become a hyperconnected oncology biomarker led by NSCLC.

With NSCLC prescribers already prescribing PD-L1 testing with ALK, EGFRm and KRAS, regardless of guidelines, and combining PD-L1 testing with ALK, etc., it seems likely that PD-L1 will fit alongside more established biomarkers and become more integrated. And yet this is only one year after launch, when PD-L1 testing is at the beginning of its journey to clinical relevance in oncology but is, relatively speaking, already more integrated into oncology clinical trials than other biomarkers were 18 months post-launch.

The Anti PD-1 therapy class of drugs could make $32bn per annum but much of this expected revenue depends upon the still underdeveloped PD-L1 testing market. It will be interesting to observe the PD-L1 space as it develops and the impact of the biomarker is felt, but it will be equally interesting to keep track of our predictions. Some of them are already being proved right.

CTA Image PDL1 webinar


Webinars & Podcasts

August 9th, 2018
Podcast: Oncology Patient Research
Why do we need to talk biomarkers with patients? Senior Director of Market Research at Diaceutics, Marianne Fillion, recently spearheaded an effort to gather insights directly from oncology patients to get an understanding of what they know about ...
April 20th, 2018
Podcast: PM Readiness Report 2018
Peter Keeling discusses the landscape and challenges for precision medicine, companion diagnostics, CDx or biomarker and conduit diagnostics are discussed including global laboratory test data analysis and forecasts for budget impact and value.
View all

Expert Insights

April 19th, 2018
The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that cove...
January 19th, 2018
What does the EU IVD Regulation mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the Regulati...
View all expert insights

Competitive Benchmarking Reports

March 16th, 2018
PM Readiness Report 2018 Summary
March 14th, 2017
Pharma Readiness for Diagnostic Integration 2017
View all reports


May 23rd, 2019
Diaceutics reviews the ongoing debate on diagnostics reform legislation
Thought leaders at Diaceutics recently authored a peer-reviewed article that covers the ongoing national debate over diagnostics reform legislation in the United States. The article is now available online ahead of print in the Journal of Molecula...
September 11th, 2018
BRAF mutation testing in melanoma – Poster presented at European Congress of Pathology 2018
BRAF mutation testing in melanoma: a study including Austria, Germany and UK, highlighting concordance for current technologies, and potential requirement of more sensitive technologies in future applications.
View all publications